| SNCAIP Gene |
|---|
| Gene Symbol | SNCAIP |
| Full Name | Synphilin-1 (Alpha-Synuclein Interacting Protein) |
| Chromosomal Location | 5q23.1 |
| NCBI Gene ID | [10407](https://www.ncbi.nlm.nih.gov/gene/10407) |
| OMIM | [603516](https://www.omim.org/entry/603516) |
| Ensembl ID | ENSG00000145341 |
| UniProt ID | [O60341](https://www.uniprot.org/uniprot/O60341) |
| Protein Length | 777 amino acids |
| Protein Class | Scaffold protein, alpha-synuclein interactor |
| Associated Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/lewy-body-dementia), [Multiple System Atrophy](/diseases/multiple-system-atrophy) |
SNCAIP (Synphilin-1) encodes a protein that was originally identified through its direct interaction with alpha-synuclein, the protein that forms the characteristic Lewy bodies in Parkinson's Disease and related synucleinopathies. Synphilin-1 is a 777-amino acid protein that plays critical roles in protein aggregation, degradation pathways, and neuronal survival. It has emerged as an important player in the pathogenesis of neurodegenerative diseases, particularly those involving alpha-synuclein pathology.
The protein serves multiple functions in the nervous system, acting as a scaffold that brings together various proteins involved in protein quality control, synaptic function, and cell death pathways. SNCAIP mutations and variants have been associated with increased risk of Parkinson's disease, particularly in combination with SNCA (alpha-synuclein) multiplications.
¶ Discovery and Nomenclature
SNCAIP was first identified in 2001 through yeast two-hybrid screening as a protein that directly interacts with alpha-synuclein. The gene name reflects its identity as the "alpha-synuclein interacting protein." Synphilin-1 (a contraction of "synuclein/philin") highlights its relationship to synuclein family proteins.
¶ Protein Structure and Function
¶ Domain Architecture
Synphilin-1 contains several distinctive structural domains:
- N-terminal domain (aa 1-200): Contains regions involved in alpha-synuclein binding
- Central domain (aa 200-500): Scaffold function, protein-protein interactions
- Coiled-coil regions (aa 300-400): Mediates oligomerization
- C-terminal domain (aa 500-777): Contains acidic regions and phosphorylation sites
- Ankyrin repeat domain (aa 150-300): Protein interaction module
Synphilin-1 binds directly to alpha-synuclein through:
- Central region interaction (aa 100-300)
- Coiled-coil domain involvement
- The interaction is believed to be phosphorylation-dependent
This binding facilitates:
- Co-aggregation of both proteins into Lewy bodies
- Formation of toxic oligomers
- Sequestration of proteins into inclusions
- Template for spreading pathology
Synphilin-1 interacts with the SNARE machinery:
- Direct binding to SNAP25
- Modulation of SNARE complex assembly
- Regulation of neurotransmitter release
- Connection to synaptic vesicle cycling
Synphilin-1 is subject to ubiquitination by multiple E3 ligases:
- SIAH-1 (Seven in Absentia Homolog 1): Promotes proteasomal degradation
- Parkin: E3 ligase mutated in familial PD
- Other ligases: Contribute to quality control
SNCAIP shows characteristic expression in the nervous system:
- Substantia nigra: High expression in dopaminergic neurons
- Cerebral cortex: Strong expression in all cortical layers
- Hippocampus: Particularly in CA regions and dentate gyrus
- Striatum: Moderate expression in medium spiny neurons
- Cerebellum: Lower expression in Purkinje cells
¶ Cellular and Subcellular Localization
- Cytosolic: Major cellular compartment
- Membrane-associated: Synaptic vesicle fractions
- Synaptic terminals: Enriched in presynaptic compartments
- Lewy bodies: Co-localizes with alpha-synuclein inclusions
SNCAIP variants modify PD risk through several mechanisms:
- S481A variant: Associated with increased PD risk in SNCA multiplication carriers
- Other coding variants: May affect protein function
- Promoter variants: May alter expression levels
¶ Lewy Body Pathology
Synphilin-1 is a major component of Lewy bodies:
- Co-localizes with alpha-synuclein in classic Lewy bodies
- Present in cortical and brainstem Lewy bodies
- Found in both sporadic and familial PD cases
- May serve as a scaffold for inclusion formation
Synphilin-1 promotes alpha-synuclein aggregation through:
- Physical interaction: Direct binding facilitates nucleation
- Oligomer formation: Creates toxic intermediate species
- Template effect: May seed further aggregation
- Cell-to-cell spread: Possible prion-like propagation
Impaired degradation contributes to accumulation:
- Ubiquitin-proteasome system: Primary degradation pathway
- SIAH-1 mediated: E3 ligase targeting for proteasome
- Autophagy-lysosome pathway: May handle larger aggregates
- Impaired clearance: Contributes to aggregate accumulation
SNCAIP is directly linked to PD pathogenesis:
- Genetic risk: Variants modify disease risk
- Lewy body component: Major structural element
- Pathogenic mechanisms: Multiple, including aggregation and degradation
- Therapeutic target: Promising for intervention
- Synphilin-1 inclusions in DLB brain
- Interacts with alpha-synuclein strains
- Contributes to cortical pathology
- Less prominent synphilin-1 pathology
- Distinct aggregation mechanisms
- May differ from PD/DLB
- Incidental Lewy body disease: Preclinical stage
- Parkinsonism-plus syndromes: Variable involvement
Synphilin-1 interacts with multiple quality control proteins:
- SIAH-1: E3 ubiquitin ligase for degradation
- Parkin: PD-associated E3 ligase
- Ubiquitin: Conjugation to target proteins
- Proteasome subunits: Degradation machinery
- HSP70: Molecular chaperone
Synphilin-1 intersects with several signaling pathways:
- Apoptosis pathways: Modulation of cell death
- Dopamine signaling: Regulation of neurotransmission
- Mitochondrial function: Effects on energy metabolism
- Calcium homeostasis: Synaptic calcium regulation
Synphilin-1 participates in synaptic biology[@eng2006]:
- Synaptic vesicle cycling: Regulates release
- SNARE complex assembly: Modulates fusion
- Dopamine release: Particularly in striatal neurons
- Synaptic plasticity: Activity-dependent changes
Targeting the SNCAIP-SNCA interaction:
- Peptide inhibitors: Block protein-protein interaction
- Small molecules: Prevent complex formation
- Antibody-based: Target interaction domains
Enhancing protein clearance:
- SIAH-1 inhibitors: Prevent excessive degradation
- Proteasome enhancers: Promote aggregate clearance
- Combination approaches: Multiple mechanisms
- RNAi: Reduce SNCAIP expression
- CRISPR editing: Correct risk variants
- Gene replacement: Not applicable (gain-of-function)
Promising therapeutic strategies:
- Alpha-synuclein aggregation blockers: May act on SNCAIP interaction
- SIAH-1 modulators: Alter degradation pathways
- Neuroprotective agents: Target multiple pathways
- Repositioned drugs: FDA-approved compounds
Transgenic approaches:
- Neuron-specific promoters (TH, Synapsin, CamKII)
- Wild-type SNCAIP overexpression
- Mutant SNCAIP lines
- Conditional expression systems
Phenotypic characterization:
- Age-dependent pathology
- Motor behavioral deficits
- Cognitive impairments
- Neurochemical changes
Limitations:
- Lack of robust Lewy body formation
- Mild phenotype in some lines
- Species differences in aggregation
- Transient knockdown (morpholinos)
- Stable transgenic lines
- Behavioral assays (locomotion, learning)
- Live imaging capability
- Homologous gene (Snrip)
- Pan-neuronal expression
- Behavioral readouts
- Genetic interactors
- Co-immunoprecipitation studies
- Mass spectrometry proteomics
- Post-translational modification analysis
- Ubiquitination assays
- Protease susceptibility assays
- Confocal microscopy
- Electron microscopy
- Super-resolution imaging (STED, PALM)
- Live cell imaging
- PET imaging
- Patch-clamp electrophysiology
- Calcium imaging
- Neurotransmitter measurement (HPLC, ELISA)
- Behavioral testing (rotarod, cylinder, gait)
- Humans: Full-length synphilin-1 (777 aa)
- Rodents: High conservation (>90%)
- Birds: Functional orthologs present
- Fish: Zebrafish model organisms
- Invertebrates: Drosophila homolog
- Alpha-synuclein binding conserved
- Ubiquitination sites preserved
- Tissue expression patterns maintained
- Subcellular localization similar
- Genetic testing available (clinical labs)
- Protein markers in development
- Clinical criteria remain primary
- Differential diagnosis important
- Symptomatic treatment focus
- Genetic counseling for families
- Clinical trial eligibility assessment
- Supportive care strategies
- multidisciplinary approach
- Understand normal physiological function
- Elucidate precise molecular mechanisms
- Develop robust biomarkers
- Identify optimal therapeutic targets
- Enable clinical translation
-
Cryo-EM structure determination
-
Single-cell omics approaches
-
Brain organoid models
-
Advanced in vivo imaging
-
Gene editing advances
-
Alpha-synuclein aggregation blockers: May act on SNCAIP interaction
-
SIAH-1 modulators: Alter degradation pathways
-
Neuroprotective agents: Target multiple pathways
- Transient transfection: Overexpression studies
- Stable cell lines: Long-term expression
- Primary neurons: Neuronal function
- iPSC-derived models: Patient-specific disease modeling
- Transgenic mice: SNCAIP overexpression
- Double transgenic: SNCA and SNCAIP
- Knockout models: Loss-of-function studies
- Viral models: AAV-mediated expression
Animal models reveal:
- Alpha-synuclein aggregation
- Movement abnormalities
- Neurodegeneration Synaptic dysfunction
Synphilin-1 affects mitochondrial function in multiple ways:
- Mitochondrial dynamics: Alters fission/fusion balance
- Respiratory function: Impairs complex I activity
- Calcium handling: Disrupts mitochondrial calcium buffering
- Apoptosis pathway: Modulates programmed cell death
Synphilin-1 expression affects reactive oxygen species:
- Increased ROS generation
- Oxidative stress accumulation
- DNA damage
- Lipid peroxidation
- Mitophagy: Impaired clearance of damaged mitochondria
- Biogenesis: Reduced mitochondrial renewal
- Transport: Defective mitochondrial trafficking
Synphilin-1 plays important roles at the synapse:
- Altered dopamine release
- Impaired synaptic vesicle cycling
- Reduced release probability
- Abnormal vesicle replenishment
Synphilin-1 modulates the SNARE machinery:
- Direct interaction with SNAP25
- Assembly of ternary complexes
- Calcium-dependent regulation
- Release site availability
Synphilin-1 accumulation triggers ER stress:
- Unfolded protein response activation
- CHOP expression
- Caspase activation
- Cell death execution
- Cathepsin activation
- Membrane permeabilization
- Autophagosome accumulation
- Failed cargo degradation
Synphilin-1 pathology affects glial cells:
- Pro-inflammatory cytokine release
- MHC class II upregulation
- NADPH oxidase activation
- Chronic neuroinflammation
- Reactive astrogliosis
- Altered glutamate uptake
- Impaired potassium buffering
- Trophic factor secretion